National Opioid Medications Abuse Deterrence (NOMAD) study

April 2014

NDARC: Prof Louisa Degenhardt, Dr Briony Larance, Prof Michael Farrell, Ivana Kihas, Toni Hordern, Elena Cama, Gabrielle Campbell, Dr Suzanne Nielsen & Prof Richard Mattick.

Other investigators: 
A/Prof Raimondo Bruno, School of Psychology, University of Tasmania
A/Prof Robert Ali, School of Medical Sciences, University of Adelaide
A/Prof Nicholas Lintzeris, The Langton Centre, South East Sydney Local Health District Drug and Alcohol Services; and University of Sydney
Dr Apo Demirkol, The Langton Centre, South East Sydney Local Health District Drug and Alcohol Services; and University of Sydney
A/Prof Adrian Dunlop, Hunter New England Local Health District
Professor Paul Haber, Royal Prince Alfred hospital and University of Sydney
Ms Amy Peacock, University of Tasmania
Dr Nghi Phung, South West Sydney Local Health District
Dr Nancy White, School of Medical Sciences, University of Adelaide 
Other Collaborators: 
Advisory Committee
Dr Michael Aufgang, General practitioner (private practice)
Nicky Bath, CEO NSW Users and AIDS Association
Lesley Brydon, CEO, Pain Australia
Dr Malcolm Dobbin, Senior medical advisor (alcohol and drugs), Mental Health, Drugs and Regions Division, VIC Department of Health
Dr Angella Duvnjak,  Program leader, Hepatitis C & other BBVs and STIs program, AIVL 
Dr Marianne Jauncey, Medical director, Sydney Medically Supervised Injecting Centre
Mr Robert Kemp, Principal Policy Advisor (HCV), Communicable Diseases Unit, QLD Health
Professor Ann Roche, Director, National Centre for Education and Training on Addiction, Flinders University
Dr Hester Wilson, General practitioner and The Langton Centre
Project description: 

There are growing efforts by pharmaceutical companies to develop opioid formulations less prone to misuse (particularly injection), dependence and diversion to illicit markets. In Australia, the semi-synthetic opioid agonist oxycodone is available in eight different products, the most frequently prescribed controlled release formulation being OxyContin. An “abuse-deterrent” (or “tamper-resistant”) formulation of OxyContin tablets was introduced onto the Australian market on 1 April 2014.

This project will examine the level of extra-medical use of oxycodone in Australia and how it compares to extra-medical use of other opioids; whether there is less non-medical use of Reformulated Oxycontin; how pharmaceutical opioid use changes following the introduction of new opioid formulations to the market; and long term outcomes for regular non-medical users of pharmaceutical opioids. 

For more about this project: Go to NDARC's website.